Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLopez-Bonet, Eugeni
dc.contributor.authorBuxó, Maria
dc.contributor.authorCuyàs, Elisabet
dc.contributor.authorPernas, Sonia
dc.contributor.authorDorca, Joan
dc.contributor.authorÁlvarez, Isabel
dc.contributor.authorCortés Castan, Javier
dc.date.accessioned2021-04-13T14:08:29Z
dc.date.available2021-04-13T14:08:29Z
dc.date.issued2019-12-11
dc.identifier.citationLopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, et al. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med. 2019 Dec 11;8(12):2180.
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/11351/5846
dc.descriptionMetformina; Ki67; Càncer de mama
dc.description.sponsorshipThis work was supported by Grants from the Ministerio de Sanidad, Servicios Sociales e Igualdad (EC10-125, Ayudas para el Fomento de la Investigación Clínica Independiente to Begoña Martin-Castillo). Work in the Menendez laboratory is supported by the Spanish Ministry of Science and Innovation (Grant SAF2016-80639-P, Plan Nacional de l+D+I, founded by the European Regional Development Fund, Spain) and by an unrestricted research grant from the Fundació Oncolliga Girona (Lliga catalana d’ajuda al malalt de càncer, Girona). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;8(12)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMetformina
dc.subjectMama - Càncer
dc.subject.meshBreast Neoplasms
dc.subject.mesh/drug therapy
dc.titleNeoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm8122180
dc.subject.decsneoplasias de la mama
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://www.mdpi.com/2077-0383/8/12/2180
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lopez-Bonet E] Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona 17005, Spain. [Buxó M] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. [Cuyàs E] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona 08908, Spain. [Pernas S] Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona 08908, Spain. [Dorca J] Medical Oncology, Catalan Institute of Oncology, Girona 17005, Spain. [Álvarez I] Medical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián 20014, Spain. Biodonostia Health Research Institute, Donostia-San Sebastián 20014, Spain. [Cortés J] IOB Institute of Oncology, Hospital Quirónsalud, Madrid & Barcelona 08023, Spain. Medica Scientia Innovation Researcher (MedSIR), Barcelona 08007, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid31835708
dc.identifier.wos000506640400150
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-80639-P
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple